{"id":1111,"date":"2016-08-25T18:27:44","date_gmt":"2016-08-25T12:57:44","guid":{"rendered":"https:\/\/delveinsightblog.wordpress.com\/?p=1111"},"modified":"2021-07-24T12:56:31","modified_gmt":"2021-07-24T07:26:31","slug":"notizia-3","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-3","title":{"rendered":"NATCO Pharma surges; AstraZeneca falls; US patent office rules"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a017aeea2d90\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a017aeea2d90\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-3\/#NATCO_Pharma_surges_7_post_successful_Establishment_Inspection_Report_for_Chennai_Plant\" >NATCO Pharma surges 7% post successful Establishment Inspection Report for Chennai Plant<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-3\/#Stocks_of_AstraZeneca_Pharma_falls_on_receiving_termination_notice_for_Meronem\" >Stocks of AstraZeneca Pharma falls on receiving termination notice for Meronem<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-3\/#The_US_patent_office_rules_in_favour_of_Mylan_Natco_Pharmas_US_partner\" >The US patent office rules in favour of Mylan, Natco Pharma\u2019s US partner<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-3\/#Mylan_CEO_summoned_by_senators_for_%E2%80%98urgent_briefing_on_EpiPen_price\" >Mylan CEO summoned by senators for &#8216;urgent briefing&#8217; on EpiPen price<\/a><\/li><\/ul><\/nav><\/div>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"NATCO_Pharma_surges_7_post_successful_Establishment_Inspection_Report_for_Chennai_Plant\"><\/span>NATCO Pharma surges 7% post successful Establishment Inspection Report for Chennai Plant<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">NATCO pharma has reached a new high of Rs. 703 on the National Stock Exchange (NSE) as the drug maker revealed the successful Establishment Inspection Report (EIR) for Chennai Plant. The U.S. Food and Drug Administration (FDA) had inspected the chemical division of the Chennai facility during February 8 \u2013 February 12, 2016. The facility mainly caters to regulated international markets, including USA. The trading volumes on the counter jumped an over three-fold with a combined 938,841 shares changed hands on the BSE and NSE in the morning today.<\/p>\n<h3 style=\"text-align: justify;\"><\/h3>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Stocks_of_AstraZeneca_Pharma_falls_on_receiving_termination_notice_for_Meronem\"><\/span>Stocks of AstraZeneca Pharma falls on receiving termination notice for Meronem<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">AstraZeneca India fell by 8% today after receiving termination notice from AstraZeneca UK for termination of distribution arrangements for Meronem in India. This is a result of a global agreement by AstraZeneca PLC to sell the development and commercialization rights to Pfizer Inc, of its late-stage small molecule antibiotics business. Meronem has been one of the company\u2019s principle products. In March 2016, it generated 18% of the total turnover of the company.<\/p>\n<h3 style=\"text-align: justify;\"><\/h3>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"The_US_patent_office_rules_in_favour_of_Mylan_Natco_Pharmas_US_partner\"><\/span>The US patent office rules in favour of Mylan, Natco Pharma\u2019s US partner<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">Drugmaker Natco Pharma Ltd on Thursday said the US Patent and Trademark Office (PTO) has ruled in favour of its partner Mylan NV by striking down two patents held by Israel-based Teva Pharmaceutical Industries Ltd for its blockbuster drug Copaxone 40 mg\/mL formulation. The two US patents are 8,232,250 and 8,399,413, which are owned by Yeda Research &amp; Development Co., Ltd. and licensed to Teva Pharmaceuticals Industries Ltd. Teva is now left with three more patents to fend-off generic competition for Copaxone 40 mg. Natco said the PTO\u2019s Patent Trial and Appeal Board (PTAB) will take a decision on Mylan\u2019s third petition seeking inter partes review of US patent number 8,969,302 by 1 September.<\/p>\n<h3 style=\"text-align: justify;\"><\/h3>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Mylan_CEO_summoned_by_senators_for_%E2%80%98urgent_briefing_on_EpiPen_price\"><\/span>Mylan CEO summoned by senators for &#8216;urgent briefing&#8217; on EpiPen price<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">Amid the social storm that Mylan has been caught in due to its increased pricing for EpiPen, Senators Susan Collins (R-ME) and Claire McCaskill (D-MO) have also tightened their belt and have called for an \u201curgent briefing\u201d with Mylan CEO Heather Bresch. The meeting has been called within two weeks in order to learn the reason behind the upsurge of the pricing by about 480% since it acquired the EpiPen in 2007. The price of EpiPen in 2007 was $100, and has now increased to be over $600. Senators such as Amy Klobuchar (D-MN), Chuck Grassley (R-IA), Bernie Sanders (I-VT), and Richard Blumenthal (D-CT) have each joined in by either calling for an investigation, demanding Mylan lower the price or requesting new info.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>NATCO Pharma surges 7% post successful Establishment Inspection Report for Chennai Plant NATCO pharma has reached a new high of Rs. 703 on the National Stock Exchange (NSE) as the drug maker revealed the successful Establishment Inspection Report (EIR) for Chennai Plant. The U.S. Food and Drug Administration (FDA) had inspected the chemical division of [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":941,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[96,710,17288,412,17287],"industry":[17225],"therapeutic_areas":[17229,17278],"class_list":["post-1111","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-astrazeneca","tag-epipen","tag-meronem","tag-mylan","tag-natco-pharma","industry-pharmaceutical","therapeutic_areas-central-nervous-system","therapeutic_areas-other-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>NACTO rallies; Mylan&#039;s CEO summoned; AZ&#039;s stocks falls; Relief for Natco<\/title>\n<meta name=\"description\" content=\"NATCO pharma has reached a new high of Rs. 703 on the National Stock Exchange (NSE) as the drug maker revealed the successful Establishment...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-3\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NACTO rallies; Mylan&#039;s CEO summoned; AZ&#039;s stocks falls; Relief for Natco\" \/>\n<meta property=\"og:description\" content=\"NATCO pharma has reached a new high of Rs. 703 on the National Stock Exchange (NSE) as the drug maker revealed the successful Establishment...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-3\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2016-08-25T12:57:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/09021626\/news-banner.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1440\" \/>\n\t<meta property=\"og:image:height\" content=\"576\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"NACTO rallies; Mylan's CEO summoned; AZ's stocks falls; Relief for Natco","description":"NATCO pharma has reached a new high of Rs. 703 on the National Stock Exchange (NSE) as the drug maker revealed the successful Establishment...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-3","og_locale":"en_US","og_type":"article","og_title":"NACTO rallies; Mylan's CEO summoned; AZ's stocks falls; Relief for Natco","og_description":"NATCO pharma has reached a new high of Rs. 703 on the National Stock Exchange (NSE) as the drug maker revealed the successful Establishment...","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-3","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2016-08-25T12:57:44+00:00","article_modified_time":"2021-07-24T07:26:31+00:00","og_image":[{"width":1440,"height":576,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/09021626\/news-banner.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-3","url":"https:\/\/www.delveinsight.com\/blog\/notizia-3","name":"NACTO rallies; Mylan's CEO summoned; AZ's stocks falls; Relief for Natco","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-3#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-3#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/09021626\/news-banner.jpg","datePublished":"2016-08-25T12:57:44+00:00","dateModified":"2021-07-24T07:26:31+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"NATCO pharma has reached a new high of Rs. 703 on the National Stock Exchange (NSE) as the drug maker revealed the successful Establishment...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-3"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-3#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/09021626\/news-banner.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/09021626\/news-banner.jpg","width":1440,"height":576},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/09021626\/news-banner-300x120.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AstraZeneca<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">EpiPen<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Meronem<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Mylan<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">NATCO Pharma<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AstraZeneca<\/span>","<span class=\"advgb-post-tax-term\">EpiPen<\/span>","<span class=\"advgb-post-tax-term\">Meronem<\/span>","<span class=\"advgb-post-tax-term\">Mylan<\/span>","<span class=\"advgb-post-tax-term\">NATCO Pharma<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 10 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Aug 25, 2016","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Aug 25, 2016 6:27 pm","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1111","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=1111"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1111\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/941"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=1111"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=1111"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=1111"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=1111"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=1111"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}